A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Barclays has nudged Vertex Pharmaceuticals’ price target to $499, despite a mixed bag in its Q1 performance. Vertex saw a 3% ...

Shares of Vertex Pharmaceuticals Inc. VRTX shed 3.38% to $434.82 Wednesday, on what proved to be an all-around favorable ...

Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 ...